Primary liver tumors are rare in childhood. Hepatoblastoma is the most prevalent and has a variable clinical presentation. The initial approach requires clinical suspicion, histopathological confirmation, and measurement of AFP levels, in addition to PRETEXT staging by abdominal computed tomography. PET-CT is useful in metastatic disease for diagnosis and evaluation of therapeutic response. Pulmonary metastases at the time of diagnosis are frequent, while bone metastases are rare. We present the case of an infant with a history of metastatic hepatoblastoma, multiple relapses, and poor response to multimodal management. The patient had bone metastases demonstrated by PET-CT imaging.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482079 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2022.08.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adjuvant radiation improves survival outcomes in adrenocortical carcinoma: A population-based study.
Medicine (Baltimore)
January 2025
Department of Urology, Shiyan People's Hospital, Jinzhou Medical University Training Base, Shiyan, China.
The aim of this study was to evaluate the clinical benefits and outcomes of adjuvant radiation therapy on adrenocortical carcinoma (ACC) patients. All patients with ACC that were reported between 2010 and 2015 were identified from the Surveillance, Epidemiology, and End Results database. A forward-stepwise Cox proportional hazards regression was used to identify independent risk factors.
View Article and Find Full Text PDFEfficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.
Int J Cancer
January 2025
Department of Medical Oncology, Shanghai East Hospital of Tongji University, Shanghai, China.
This study aimed to assess the efficacy and safety of three dosing regimens of JMT103 in patients with bone metastases from solid tumors. Eligible patients were randomly assigned to receive JMT103 subcutaneously, 120 mg every 4 weeks (Cohort 1), 120 mg every 8 weeks (Cohort 2), or 180 mg every 8 weeks (Cohort 3) for up to 49 weeks. The primary endpoint was change from baseline to Week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr).
View Article and Find Full Text PDFAccurate survival prediction of patients with long-bone metastases is challenging, but important for optimizing treatment. The Skeletal Oncology Research Group (SORG) machine learning algorithm (MLA) has been previously developed and internally validated to predict 90-day and 1-year survival. External validation showed promise in the United States and Taiwan.
View Article and Find Full Text PDFImmunotherapy combined with chemotherapy without locoregional radiotherapy in metastatic nasopharyngeal carcinoma: two case reports and a literature review.
Front Immunol
January 2025
Department of Otolaryngology, Changhai Hospital, Naval Medical University, Shanghai, China.
Background: There is no consensus regarding the optimal regimen for metastatic nasopharyngeal carcinoma (dmNPC). Locoregional intensity modulated radiotherapy (LRRT) following palliative chemotherapy (PCT) has been shown to prolong the overall survival (OS) and improve the progression-free survival (PFS) of patients with dmNPC, compared with PCT alone. However, patients with a high tumor burden do not benefit from additional LRRT, which inevitably results in toxicity.
View Article and Find Full Text PDFNasopharyngeal carcinoma (NPC) is an epithelial malignancy commonly associated with Epstein-Barr virus infection. While bone, liver, and lung metastases are well-documented, central nervous system (CNS) involvement, particularly spinal and meningeal metastases, is extremely rare. We present a 41-year-old male with nasal obstruction and diplopia, diagnosed with locally advanced NPC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!